Oseltamivir for influenza

Doshi, Peter; Heneghan, Carl; Jefferson, Tom

doi:10.1016/s0140-6736(15)01282-9

Cited by 7 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(g) Effect of SSP administration for 4 weeks on the organ coefficient of SD rats treating H5N1 infection. Oseltamivir, amantadine, and rimantadine are neuraminidase inhibitors that have been practiced to inhibit H5N1 replication and to prevent virus spread humans (Doshi, Heneghan, & Jefferson, 2016;Jacob et al, 2016). However, generation of oseltamivir, amantadine, and rimantadine resistance H5N1 during treatment was reported (Jacob et al, 2016;Singh & Soliman, 2015).…”

Section: Discussionmentioning

confidence: 99%

Broad‐spectrum antiviral activity of Spatholobus suberectus Dunn against SARS‐CoV‐2, SARS‐CoV‐1, H5N1, and other enveloped viruses

Liu

Kwan

Cao

et al. 2022

Phytotherapy Research

View full text Add to dashboard Cite

The current COVID‐19 pandemic caused by SARS‐Cov‐2 is responsible for more than 6 million deaths globally. The development of broad‐spectrum and cost‐effective antivirals is urgently needed. Medicinal plants are renowned as a complementary approach in which antiviral natural products have been established as safe and effective drugs. Here, we report that the percolation extract of Spatholobus suberectus Dunn (SSP) is a broad‐spectrum viral entry inhibitor against SARS‐CoV‐1/2 and other enveloped viruses. The viral inhibitory activities of the SSP were evaluated by using pseudotyped SARS‐CoV‐1 and 2, HIV‐1ADA and HXB2, and H5N1. SSP effectively inhibited viral entry and with EC50 values ranging from 3.6 to 5.1 μg/ml. Pre‐treatment of pseudovirus or target cells with SSP showed consistent inhibitory activities with the respective EC50 value of 2.3 or 2.1 μg/ml. SSP blocked both SARS‐CoV‐2 spike glycoprotein and the host ACE2 receptor. In vivo studies indicated that there was no abnormal toxicity and behavior in long‐term SSP treatment. Based on these findings, we concluded that SSP has the potential to be developed as a drug candidate for preventing and treating COVID‐19 and other emerging enveloped viruses.

show abstract

Section: Discussionmentioning

confidence: 99%

Broad‐spectrum antiviral activity of Spatholobus suberectus Dunn against SARS‐CoV‐2, SARS‐CoV‐1, H5N1, and other enveloped viruses

Liu

Kwan

Cao

et al. 2022

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…However, a mutation in more than 95% of influenza viruses in circulation announced M2 inhibitor to be useless in 2006 [7][8][9]. Subsequent types of anti-influenza drugs included neuraminidase inhibitors, represented by oseltamivir, zanamivir, laninamivir, and peramivir, and polymerase inhibitor baloxavir [10][11][12][13]. Regretfully, due to the drug resistance, they are all requested to be given within 2 days of symptoms to guarantee efficacy [14,15].…”

Section: Introductionmentioning

confidence: 99%

Determination of a novel anti‐influenza pinanamine‐based analog in rat plasma by liquid chromatography‐tandem mass spectrometry and its application in pharmacokinetic evaluations

Lin,

Zhao,

Yang

et al. 2024

Separation Science Plus

View full text Add to dashboard Cite

A pinanamine‐based analog, (1R,2R,3R,5S)‐N‐((3‐cyclopropylthiophen‐2‐yl)methyl)‐2,6,6‐trimethylbicyclo[3.1.1]heptan‐3‐amine (M090) was synthesized and demonstrated with anti‐influenza activity to overcome the multi‐drug resistance. Herein, a rapid and robust liquid chromatography‐tandem mass spectrometry method was developed and validated to quantify M090 in rat plasma. With simple protein precipitation by methanol, the separation of M090 was performed on a Waters BEH‐C18 column (2.1 × 100 mm, 1.7 μm) by gradient elution at 0.4 mL/min with mobile phases consisting of water containing 0.1 % formic acid (phase A) and methanol (phase B). M090 and clenbuterol (internal standard) were detected using multiple reaction monitoring in positive electrospray ionization mode with transitions of m/z 290.3→137.0 and m/z 277.0→203.0, respectively. The method was validated over a linear range of 1.0–2400 ng/mL with a regression coefficient of 0.9974 and no endogenous interference. The intra‐ and inter‐batch precisions were within 8.29% and accuracy ranged from 100.3% to 108.1% for M090. The validated method was utilized to evaluate the in vitro metabolic stability and in vivo pharmacokinetics of M090 in rats.

show abstract

“…Despite significant progress in the search for drugs that can suppress the replication of the influenza virus at different stages of reproduction, only three groups of drugs are used in healthcare. The three categories of anti-influenza drugs are as follows: the neuraminidase (NA) inhibitors such as oseltamivir (Tamiflu) − and zanamivir that have been approved in many countries worldwide, peramivir − and laninamivir − are approved in Japan. Peramivir is also approved in China and the Republic of Korea .…”

Section: Introductionmentioning

confidence: 99%

Naturally Occurring Isorhamnetin Glycosides as Potential Agents Against Influenza Viruses: Antiviral and Molecular Docking Studies

Bogoyavlenskiy,

Zaitseva,

Alexyuk

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Influenza remains one of the most widespread infections, causing an annual illness in adults and children. Therefore, the search for new antiviral drugs is one of the priorities of practical health care. Eight isorhamnetin glycosides were purified from Persicaria species, characterized by nuclear magnetic resonance spectroscopy and mass spectrometry and then evaluated as potential agents against influenza virus. A comprehensive in vitro and in vivo assessment of the compounds revealed that compound 5 displayed the most potent inhibitory activity with an EC 50 value of 1.2–1.3 μM, better than standard drugs (isorhamnetin 28.0–56.0 μM and oseltamivir 1.3–9.1 μM). Molecular docking results also revealed that compound 5 has the lowest binding energy (−10.7 kcal/mol) among the tested compounds and isorhamnetin (−8.1 kcal/mol). The ability of the isorhamnetin glycosides to suppress the reproduction of the influenza virus was studied on a model of a cell culture and chicken embryos. The ability of active compounds to influence the structure of the virion, as well as the activity of hemagglutinin and neuraminidase, has been demonstrated. Compound 1, 5, and 6 demonstrated the most effective inhibition of virus replication for all tested viruses. Molecular dynamics simulation techniques were run for 100 ns for compound 5 with two protein receptors Hem (1RUY) and Neu (3BEQ). These results revealed that the Hem-complex system acquired a relatively more stable conformation and even better descriptors than the other Neu-complex studied systems, suggesting that it can be an effective inhibiting drug toward hemagglutinin than neuraminidase inhibition. Based on the reported results, compound 5 can be a good candidate to be evaluated for effectiveness in preclinical testing.

show abstract

Oseltamivir for influenza

Cited by 7 publications

References 7 publications

Broad‐spectrum antiviral activity of Spatholobus suberectus Dunn against SARS‐CoV‐2, SARS‐CoV‐1, H5N1, and other enveloped viruses

Broad‐spectrum antiviral activity of Spatholobus suberectus Dunn against SARS‐CoV‐2, SARS‐CoV‐1, H5N1, and other enveloped viruses

Determination of a novel anti‐influenza pinanamine‐based analog in rat plasma by liquid chromatography‐tandem mass spectrometry and its application in pharmacokinetic evaluations

Naturally Occurring Isorhamnetin Glycosides as Potential Agents Against Influenza Viruses: Antiviral and Molecular Docking Studies

Contact Info

Product

Resources

About